Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his twelve (12) year at Scimitar's RegMedicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and high-impact... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Earnings Report Card, Q2/12, Regenerative Medicine Universe 3 comments
    Aug 29, 2012 12:29 PM | about stocks: ASTM, BMTI, BTX, CUR, CYTX, DNDN, GERN, NBS, OPXA, OSIR, STEM, TNGN

    Report Card

    An earnings release is a 'report card' of sorts for a public stem cell company. The current LPS (loss per share) standings reflect the universes' investing status; then add in their cash position for a better snapshot!

    By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity of stem cell research and whether or not it deserves their investment.

    For Q2/12 ending 6/30/12, earnings continue to be announced so far:

    • Tengion (OTCQB:TNGN) an adjusted net loss of $4.54M or $0.1.89 per share with $3.7M in cash with bankrupcy potential;
    • Cytomedix (OTC: CMXI) net loss of $7.46M or $0.09 per share with $8.55M in cash;
    • BioLife Solutions (OTC: BLFS) net loss of $499k or $0.01 per share with $155K in cash;
    • NeoStem (AMEX: NBS) net loss of $20.59MM or $0.15 per share with $11.6M? in cash;
    • Verastem (VSTN) net loss of $6.8M or $0.34 per share with $104.3M in cash;
    • Opexa (OPXA) net loss of $2.16M or $0.09 per share with $5.69M in cash<7/12, convertible offering>;
    • Athersys (ATHX) net loss of $3.7M or $0.103per share with $10.9M in cash;
    • BioTime (AMEX: BTX) net loss of $5.5M or $0.1 per share with $12.7M in cash;
    • Osiris (OSIR) net loss of $4.265M or $0.13 per share with $40.1M cash;
    • StemCells (STEM) net income of $834K or $0.03 per share with $18.162M in cash;
    • Aastrom (ASTM) net loss of $8.6M or $0.22 per share with $28.7M in cash;
    • Cytori (CYTX) net loss of $7.9M or $0.13 per share with $25.8M in cash plus $2M in receivables;
    • Neuralstem (AMEX: CUR) net loss of $2.36M or 0.04 per share with $2.539M in cash;
    • Advanced Cell Technology (OTC BB: ACTC) net loss of $4M or $o.oo per share with $9.9M in cash;
    • Dendreon (DNDN) net loss of $96.1M or 0.65 per share with $509.7m in cash;
    • Geron (GERN) net loss of $18.3M or $0.14 per share with $122.3M in cash;
    • International Stem Cell (OTC BB: ISCO) net loss of $2.47M or $0.03 per share with $4.29M in cash;
    • BioMimetic (BMTI) net loss of $6.4M or $0.23 per share and $18.64M in cash and $114.4M in short-term investments and receivables of $373.38K and pre-paid expenses of $$639.9K.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Themes: earnings Stocks: ASTM, BMTI, BTX, CUR, CYTX, DNDN, GERN, NBS, OPXA, OSIR, STEM, TNGN
Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • Dont be deceived by OPXA's earnings. They are about to start their trial any day. Their CMC was just approved and a PR is eminent.

     

    Volume has been thru the roof and PPS is up over 60% the last 3 days
    29 Aug 2012, 12:49 PM Reply Like
  • Thanks for the information. It's important for us all to keep abreast of the latest developments in what is seemingly an incredible field of medical and scientific research worldwide and a potential watershed investment for the lucky few as well.

     

    Naturally, financial health must be carefully reviewed regarding any investments related to the scientific opportunity of stem cell research.

     

    Ultimately, it is very early for this phase of biotech and one must take ample caution as to where they get their information, especially given the investment potential of the research currently underway.

     

    Thanks again.
    6 Sep 2012, 10:16 AM Reply Like
  • This is incredible , Stem Cell is the ONLY regenerative medicine stock listed here that has a net positive in earnings for Q2/2012. Thats 1 , (one) , out of 18 , (eighteen) ,stocks in the regenerative Medicine list that is currently showing (at least on paper) a last quarter positive earning.
    What makes it most INCREDIBLE to me is that I own 400 shares of it which I bought at the relative low price of $1.08 !
    3 Oct 2012, 06:06 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.